Articles by Sunnie Kim, MD
The panel covers ASPEN-O6 results, excitement around ADCs in late-line HER-2 and Claudin-positive cancers, and more.
The panel considers tislelizumab amid existing PD-1 inhibitors, zolbetuximab for Claudin-positive patients, and more.
The panel covers updates on 1L treatments for metastatic gastric cancer, including the recent approval of tislelizumab.
The panel explores advancements in early-stage esophageal cancer, emphasizing the paradigm shift toward FLOT chemotherapy.
Personalized Care in Gastric and Esophageal Cancers: Biomarkers, Diagnosis, and Treatment Approaches
The panel focuses on the management of gastroesophageal cancers, highlighting differences in presentations across regions.
Dr. Kim provides an overview of the FDA approval of tislelizumab for the treatment of advanced, metastatic esophageal cancer.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.